David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition

David Sinclair, a longevity scientist, plans to test an oral reprogramming drug in human trials as part of a $101 million XPrize competition aimed at restoring apparent age through improvements in immune, cognitive, and muscle function. His Harvard-affiliated work involves epigenetic reprogramming, which resets molecular DNA controls, and his company Life Biosciences has already initiated gene therapy trials for eye conditions.